Look up one drug

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

Apo-Teriflunomide · DIN 02500639 Manufacturer: Apotex Inc.; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand APO-TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Apotex inc · schedule Prescription

DIN 02500639: Apo-Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id APX Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02500639 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99030

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Aubagio · DIN 02416328 · not recorded Jamp Teriflunomide · DIN 02504170 · $14.9300 M-Teriflunomide · DIN 02523833 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 Nat-Teriflunomide · DIN 02500310 · $14.9300 PMS-Teriflunomide · DIN 02500434 · $14.9300 Sandoz Teriflunomide · DIN 02505843 · $14.9300 Teva-Teriflunomide · DIN 02501090 · $14.9300

Shortage status: resolved shortage (ended 2024-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02500639

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

Jamp Teriflunomide · DIN 02504170 Manufacturer: Jamp Pharma Corporation; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand JAMP TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Jamp pharma corporation · schedule Prescription

DIN 02504170: Jamp Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id JPC Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504170 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99361

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Apo-Teriflunomide · DIN 02500639 · $14.9300 Aubagio · DIN 02416328 · not recorded M-Teriflunomide · DIN 02523833 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 Nat-Teriflunomide · DIN 02500310 · $14.9300 PMS-Teriflunomide · DIN 02500434 · $14.9300 Sandoz Teriflunomide · DIN 02505843 · $14.9300 Teva-Teriflunomide · DIN 02501090 · $14.9300

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02504170

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

M-Teriflunomide · DIN 02523833 Manufacturer: Mantra Pharma Inc.; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand M-TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Mantra pharma inc · schedule Prescription

DIN 02523833: M-Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id MAT Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523833 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101289

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Apo-Teriflunomide · DIN 02500639 · $14.9300 Aubagio · DIN 02416328 · not recorded Jamp Teriflunomide · DIN 02504170 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 Nat-Teriflunomide · DIN 02500310 · $14.9300 PMS-Teriflunomide · DIN 02500434 · $14.9300 Sandoz Teriflunomide · DIN 02505843 · $14.9300 Teva-Teriflunomide · DIN 02501090 · $14.9300

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02523833

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

Nat-Teriflunomide · DIN 02500310 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand NAT-TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Natco pharma (canada) inc · schedule Prescription

DIN 02500310: Nat-Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id NAT Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02500310 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99001

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Apo-Teriflunomide · DIN 02500639 · $14.9300 Aubagio · DIN 02416328 · not recorded Jamp Teriflunomide · DIN 02504170 · $14.9300 M-Teriflunomide · DIN 02523833 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 PMS-Teriflunomide · DIN 02500434 · $14.9300 Sandoz Teriflunomide · DIN 02505843 · $14.9300 Teva-Teriflunomide · DIN 02501090 · $14.9300

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02500310

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

PMS-Teriflunomide · DIN 02500434 Manufacturer: Pharmascience Inc.; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand PMS-TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Pharmascience inc · schedule Prescription

DIN 02500434: PMS-Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id PMS Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02500434 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99011

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Apo-Teriflunomide · DIN 02500639 · $14.9300 Aubagio · DIN 02416328 · not recorded Jamp Teriflunomide · DIN 02504170 · $14.9300 M-Teriflunomide · DIN 02523833 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 Nat-Teriflunomide · DIN 02500310 · $14.9300 Sandoz Teriflunomide · DIN 02505843 · $14.9300 Teva-Teriflunomide · DIN 02501090 · $14.9300

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02500434

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

Sandoz Teriflunomide · DIN 02505843 Manufacturer: Sandoz Canada Inc.; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand SANDOZ TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Sandoz canada incorporated · schedule Prescription

DIN 02505843: Sandoz Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id SDZ Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02505843 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99522

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Apo-Teriflunomide · DIN 02500639 · $14.9300 Aubagio · DIN 02416328 · not recorded Jamp Teriflunomide · DIN 02504170 · $14.9300 M-Teriflunomide · DIN 02523833 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 Nat-Teriflunomide · DIN 02500310 · $14.9300 PMS-Teriflunomide · DIN 02500434 · $14.9300 Teva-Teriflunomide · DIN 02501090 · $14.9300

Shortage status: resolved shortage (ended 2026-01-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02505843

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 647 For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria: 1. 18 years of age or older; AND 2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following: - 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR - 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location; Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below: - Additional clinical attack - Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan) - Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below: - additional clinical attack implicating different CNS site - 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord AND 3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND 4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND 5. Teriflunomide is used as monotherapy; AND 6. The drug request is from a neurologist experienced in the management of RRMS. Exclusion Criteria: 1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed. 2. Patients with an EDSS score equal to or greater than 7.0. LU Authorization Period: 1 year Renewal Criteria: Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0. Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program. Renewal duration: 1 year Recommended Dose: 14mg once daily Refer to the product monograph for prescribing information. Exceptional Access criteria on record are for Brand(s): Aubagio; DOSAGE FORM/ STRENGTH: 14 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Teriflunomide Brand(s): Aubagio DOSAGE FORM/ STRENGTH: 14 mg tablet Moved to ODB formulary effective May 31, 2023 This drug is available on the ODB formulary as a Limited Use Benefit. Please refer to the formulary for the updated ODB funding criteria. 241 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 241, record 142, corpus 2025-01-01; name match only, not an eligibility decision

Teva-Teriflunomide · DIN 02501090 Manufacturer: Teva Canada Limited; listing date 2022-07-29 Health Canada: Marketed since 2022-05-16 · brand TEVA-TERIFLUNOMIDE · ATC L04AK02 TERIFLUNOMIDE · form Tablet · route Oral · ingredients TERIFLUNOMIDE 14 MG · company Teva canada limited · schedule Prescription

DIN 02501090: Teva-Teriflunomide Raw flags: sec12=Y, sec3=Y Item: 920000701; group id 967; item number 2297; lccId 00370; manufacturer id TEV Source form: Tab; strength: 14mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.9300; ministry $14.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02501090 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99074

Interchangeable products

Ach-Teriflunomide · DIN 02502933 · $14.9300 Apo-Teriflunomide · DIN 02500639 · $14.9300 Aubagio · DIN 02416328 · not recorded Jamp Teriflunomide · DIN 02504170 · $14.9300 M-Teriflunomide · DIN 02523833 · $14.9300 Mar-Teriflunomide · DIN 02500469 · $14.9300 Nat-Teriflunomide · DIN 02500310 · $14.9300 PMS-Teriflunomide · DIN 02500434 · $14.9300 Sandoz Teriflunomide · DIN 02505843 · $14.9300

Shortage status: active shortage (reported 2025-11-19, estimated to end 2026-09-30, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02501090

Shortage record checked 2026-09-13T08:10:21.292534+00:00